Curis Shares to Reverse Split on Monday, July 6th (NASDAQ:CRIS)

Curis, Inc. (NASDAQ:CRIS)’s stock is set to reverse split before the market opens on Monday, July 6th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, July 5th.

Curis Stock Down 17.9%

Shares of Curis stock traded down $0.08 during trading on Thursday, hitting $0.35. 2,359,126 shares of the company were exchanged, compared to its average volume of 8,975,921. Curis has a fifty-two week low of $0.18 and a fifty-two week high of $2.01. The stock has a market capitalization of $13.51 million, a price-to-earnings ratio of -0.29 and a beta of 3.08. The firm has a 50 day moving average price of $0.49 and a 200 day moving average price of $0.75.

Curis (NASDAQ:CRIS) last announced its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.92). Analysts predict that Curis will post -1.27 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on CRIS shares. Wall Street Zen raised Curis to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research note on Monday, April 20th. Zacks Research lowered shares of Curis from a “hold” rating to a “strong sell” rating in a report on Friday, May 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Curis in a research note on Friday, March 20th. One analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $17.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CRIS. Squarepoint Ops LLC lifted its stake in shares of Curis by 17.9% during the 3rd quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 8,973 shares during the period. Jane Street Group LLC grew its position in shares of Curis by 71.8% in the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 10,586 shares during the period. XTX Topco Ltd purchased a new stake in shares of Curis in the fourth quarter valued at $26,000. Maverick Capital Ltd. increased its stake in Curis by 7.8% in the second quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock valued at $1,472,000 after purchasing an additional 49,554 shares during the last quarter. Finally, Focused Wealth Management Inc increased its stake in Curis by 83.4% in the first quarter. Focused Wealth Management Inc now owns 109,746 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 49,900 shares during the last quarter. 29.97% of the stock is currently owned by institutional investors and hedge funds.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.